| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H25N6O8P |
| Molecular Weight | 532.4431 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@H]4O[C@@H](O[C@@H]34)\C=C\C5=CC=CC=C5)C2=NC=N1
InChI
InChIKey=NXHAXEBZOXCDKD-XIXRRVGJSA-N
InChI=1S/C22H25N6O8P/c1-2-23-22(29)27-19-16-20(25-11-24-19)28(12-26-16)21-18-17(14(34-21)10-33-37(30,31)32)35-15(36-18)9-8-13-6-4-3-5-7-13/h3-9,11-12,14-15,17-18,21H,2,10H2,1H3,(H2,30,31,32)(H2,23,24,25,27,29)/b9-8+/t14-,15+,17-,18-,21-/m1/s1
Regrelor (INS50589) is a P2Y(12) ADP-receptor antagonist that regulates platelet function. Regrelor was found to be well-tolerated and have reversible effects. Its potential therapeutic utility in various cardiovascular settings has been studied. Initial results of canine models suggested that regrelor should be effective in protecting platelet function and reducing blood loss in human patients undergoing open-heart surgery. A phase II study testing regrelor for its safety and efficacy in reduction of postoperative bleeding and blood product transfusion was terminated due to adverse effects.
Originator
Approval Year
PubMed
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
